GE will demonstrate at RSNA 2014 its newly FDA-approved tomosynthesis solution.
GE Healthcare will showcase at RSNA 2014 its new breast imaging 3D tomosynthesis solution, SenoClaire.
SenoClaire, which received FDA approval in August, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, which removes the potential from motion from the tube helping to preserve microcalcification sharpness and avoid image blur, GE said.
The SenoClaire has no increase in dose from a 2D standard mammogram to a 3D view, GE said.
[[{"type":"media","view_mode":"media_crop","fid":"29834","attributes":{"alt":"GE SenoClaire","class":"media-image media-image-right","id":"media_crop_954194364083","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3114","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 240px; width: 300px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]
Radiology Experience, Breast Density and Screening Mammography: What New Research Reveals
October 4th 2024In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.
Comparing Digital Breast Tomosynthesis to Digital Mammography: What a Long-Term Study Reveals
September 17th 2024In a study involving over 272,000 breast cancer screening exams, digital breast tomosynthesis (DBT) had a higher breast cancer detection rate and a lower rate of advanced cancer presentation at the time of diagnosis in comparison to digital mammography.